



Department
of Health

Medicaid NYRx

NYRx Education & Outreach MCO Newsletter

[Highlights](#) | [Publications](#) | [Quick Links](#) | [About](#) | [Weekly Webinars](#) | [Contact](#)

February 20, 2026

Highlights

What is an IVN and how can I obtain one?

An Individual Verification Number (IVN) is a unique identifier assigned to individuals associated with a Managed Care Organization (MCO) or State agency who do not have a National Provider Identifier (NPI), but who require access to the NYRx E&O Team to discuss member protected health information (PHI).

The IVN is used to verify the caller's identity and serves as the required HIPAA authorization. Access Request Contacts (ARCs) must complete a form to authorize call center access for identified Designated Users (DUs). ARCs are primary points of contact for their organization typically consisting of leaders, directors, and compliance officers. Authorized access to PHI must be limited to what is necessary based on the DU's job responsibilities. Once the request is approved, the DU will receive an email with their assigned IVN and instructions for contacting the call center.

The NYRx E&O team recommends that all organizational staff who directly support care coordination functions, including case workers and case managers, obtain an IVN.

For questions related to the form, contact NYRxEO@primetherapeutics.com.



[Top ↑](#)

Compound Policy Coverage Update

Effective February 5, 2026, **NYRx, the Medicaid Pharmacy Program** implemented system changes to enforce policy for certain compound claims.

The following ingredients, when used in topical compounds, **are excluded from coverage by NYRx**:

- **Amitriptyline**
- **Baclofen**
- **Clonidine**
- **Cyclobenzaprine**
- **Diclofenac**
- **Fluconazole**
- **Itraconazole**
- **Ketoprofen**
- **Lidocaine**


Note: The above products lack compendia support or are available in commercial products when used topically.

Affected drugs will deny for **eMedNY edit #00551**, Item Not Eligible for Payment on Fill Date. The National Council for Prescription Drug Programs reject code is "MR," Product not on Formulary.

For more information, see [Compound Policy Coverage Update](#).



[Top ↑](#)



NYRx Drug Coverage Overview: Trelegy Ellipta

The Preferred Drug Program (PDP) promotes the use of less expensive, equally effective drugs within specific drug classes when medically appropriate. Drugs subject to the PDP are listed on the NYRx Preferred Drug List (PDL). Trelegy Ellipta® is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist (LABA).

Trelegy Ellipta® is non-preferred and will require a PA. The following alternative agents are preferred (PA not needed) and can be used in combination:

- **Arnuity Ellipta®** BLTG (fluticasone furoate)
- **Anoro Ellipta®** BLTG (umeclidinium and vilanterol)

For more information, see [NYRx Drug Coverage Overview: Trelegy Ellipta](#).



NYRx Brand Less Than Generic Program Update

Effective February 19, 2026, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Cipro® HC** will be **ADDED** to the program.
- **Daytrana®**, **Exelon® patch**, **Jynarque®**, **Motegrity®**, **Nexavar®**, **Trileptal® suspension**, and **Votrient®** will be **REMOVED** from the program.

For more information, see [NYRx Brand Less Than Generic Program Update](#).



[Top ↑](#)

NYRx Notice to Providers: Medicaid Coverage of Penicillin G Benzathine



UPDATE: As of January 5, 2026, the FDA reports continued supply issues with Bicillin L-A (penicillin G benzathine injectable suspension) and Extencilline (benzathine benzylpenicillin injection, powder for suspension).

In response to this shortage, Lentocilin© (benzathine benzylpenicillin tetrahydrate injection, powder for suspension) has been added to the Medicaid Pharmacy list of reimbursable drugs.

Medicaid managed care plans should allow coverage of Lentocilin under their medical benefit, effective immediately.

For more information, see [NYRx Notice to Providers: Medicaid Coverage of Penicillin G Benzathine](#).



[Top ↑](#)

Publications

Click to access [NYRx, the Medicaid Pharmacy Program](#) website for these publications and more.

- Billing & Coordination of Benefits
- Drug Class Coverage Overviews
- Newsletters
- Notifications
- Prior Authorization Information

[Top ↑](#)

Quick Links



[NYRx Preferred Drug List](#)



[NYRx Preferred Drug Quick List](#)



[NYRx eMedNY Formulary File](#)



[NYRx Brand Less Than Generic Program Updates](#)



[NYRx Preferred Diabetic Supply Program](#)

[Top ↑](#)

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:



- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

[Top ↑](#)

Weekly Webinars

To register, please visit the [NYRx Education & Outreach](#) website.

Prescriber Webinar

Mondays

12 PM – 1 PM ET

Pharmacy Webinar

Wednesdays

12 PM – 1 PM ET

NYRx, the Medicaid Pharmacy Program

Fridays

12 PM – 1 PM ET

[Top 1](#)

Contact Us

Office Hour Q&A Pop-In

Mondays and Wednesdays

12 PM – 1 PM ET

[Click here to join.](#)



Meet with the Team

The NYRx E&O team meets with various stakeholders throughout the month. Would you like to request a meeting with us? Click [here](#).

NYRx E&O Call Center

1-833-967-7310

Monday – Friday

8 AM – 5 PM ET

Excludes Holidays



[Top 1](#)

 [Visit Our Website](#)

 [Email Us](#)

 [NYRx E&O Channel](#)

 [NYS Public Health Now Podcast](#)